However, this study suffered from some limitations: (i) the prognostic power of the comparison of the p.G12C variants against RAS wild-type tumours; (ii) the absence of complete RAS testing in at least three studies (FIRE-3, AIO KRK 0604, and RO91); (iii) the treatments’ heterogeneity (patients came from different institutions and not all the wild-type patients received anti-EGFR-based drugs); and (iv) the fact that RAS testing was performed using different techniques and, in some studies, in different laboratories rather than being centralized. This evidence concerns the gene EGFR and neoplasm.